Essential diabetes drugs’ prices are constrained by a pricing authority
Two essential anti-diabetic medications—Sitagliptin-Metformin combination and Linagliptin-Metformin combination—have been placed under price control by India’s drug pricing authority. The National Pharmaceutical Pricing Authority has set retail prices for 45 drug formulations, including the two anti-diabetic medications (NPPA). Since Merck Sharp and Dohme’s (MSD) Sitagliptin patent expired last month, several generic versions of the drug have […]
Continue Reading